The activity of gemcitabine in advanced non-small-cell lung cancer
- VernacularTitle:吉西他滨治疗晚期非小细胞肺癌的现状
- Author:
Yang LUO
;
Xiangru ZHANG
;
- Publication Type:Journal Article
- Keywords:
lung tumor;
non small cell lung cancer;
gemcitabine
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC). It is validated that the response rate of the single agent gemcitabine was consistently above 20%, median survival was 34 weeks and it could improve the disease related symptoms with well toleranced toxicities by many clinical studies. This report reviews the clinical studies of gemcitabine in the patients with advanced NSCLC.
